ArticleSurgical endoscopy2026
A prospective cohort study evaluating disease-specific mortality in patients with early-stage Barrett's esophagus-related neoplasia following endoscopic therapy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEndoscopic eradication therapy (EET) for Barrett's esophagus (BE)-related neoplasia is safe and effective in the short term, however there are limited data on long-term outcomes. We aim to provide further evidence on the long-term efficacy of EET in patients with BE-related high-grade dysplasia (HGD) or low-risk T1 esophageal adenocarcinoma (EAC).
methodsThis prospective cohort study enrolled patients with early BE-related neoplasia at a single tertiary referral center between January 2005 and December 2022. We included patients who had a baseline histological diagnosis of HGD, T1a or superficial T1b EAC (invasion into the submucosa less than 500 µ) and received endoscopic therapy with either primary radiofrequency ablation or endoscopic resection (ER). Our primary outcome assessed disease-specific mortality (DSM), which is defined as death following progression to advanced adenocarcinoma not amenable to curative treatment. Secondary outcomes evaluate overall survival, endoscopic recurrence, progression to esophagectomy and major post-procedure complications.
resultsWe included 330 patients (HGD n = 135; T1a EAC n = 170; T1b EAC n = 25), of which 283 patients were treated with primary endoscopic resection (ER) whereas 47 patients were treated with RFA alone. Median follow up was 55.35 months (IQR 36.5-86.5). DSM was 2.2% (n = 7), with no significant difference between the HGD and EAC groups (p = 0.596). Temporal analysis demonstrated outcome improvement, with 85.7% of DSM cases occurring in the 2005-2014 time period. Five-year overall survival was 88.5%. Endoscopic recurrence was found in 4.2% (n = 14) of patients and 8.8% (n = 29) of patients required surgical intervention.
conclusionIn BE-related HGD and early-stage EAC, EET was associated with a low rate of progression to surgery and endoscopic recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.